Vēres

^{1. Harper D, Gall S, Naud P, Quint W, Dubin G, Jenkins D, et al. Sustainedimmunogenicity and high efficacy against HPV-16/18 related to cervical neoplasia:long-term follow up through 6.4 years in women vaccinated with Cervarix® (GSKsHPV 16/18 AS04 candidate vaccine). Society for Gynecologic Oncologists (SGO).Tampa, Florida, USA, 2008, March 9-12.}

^{2. Wheeler C,Teixeira J, Romanowski B, De Carvalho NS, Dubin G, Schuind A. High andsustained HPV-16 and 18 antibody levels through 6.4 years in women vaccinatedwith Cervarix® (GSK HPV-16/18 AS04 vaccine). 26th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID). Graz, Austria, 2008,May 13-16.}

^{3. Zāļu apraksts Cervarix. GlaxoSmithKline, 2011}

^{4. Latvijas Vēža reģistra dati.}

^{5. Paavonen J. et al Lancet (2007:369.2161-70)}

^{6. Adv.Ther. (2009)26911):Doi.10.1007/s12.}

^{7. D. Harper, Late-breaking abstracts presented for the 39. annual meeting of the Society of Gynecologic Oncologists, Gynecologic Oncology 109 (2008), 158 - 159}

^{8. Data on file}